• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Biomea Fusion Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/5/25 4:05:08 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMEA alert in real time by email
    8-K
    false000184043900018404392025-05-052025-05-05

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 05, 2025

     

     

    Biomea Fusion, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    001-40335

    82-2520134

    (State or other jurisdiction
    of incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    900 Middlefield Road, 4th Floor

     

    Redwood City, California

     

    94063

    (Address of principal executive offices)

     

    (Zip Code)

     

    Registrant’s telephone number, including area code: 650 980-9099

     

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.0001 par value

     

    BMEA

     

    The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 5, 2025, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. The full text of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    99.1

    Press release dated May 5, 2025, furnished herewith.

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    Biomea Fusion, Inc.

     

     

     

     

    Date:

    May 5, 2025

    By:

    /s/ Michael J.M. Hitchcock

     

     

     

    Interim Chief Executive Officer, Director
    (Principal Executive Officer)

     


    Get the next $BMEA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BMEA

    DatePrice TargetRatingAnalyst
    6/3/2025$7.00Overweight
    Piper Sandler
    10/9/2024$128.00Buy
    Edward Jones
    9/27/2024$18.00Neutral → Buy
    Rodman & Renshaw
    9/27/2024$54.00Hold → Buy
    Truist
    8/29/2024$25.00Overweight
    CapitalOne
    6/11/2024Buy → Hold
    Truist
    6/7/2024$30.00 → $5.00Overweight → Equal Weight
    Barclays
    4/2/2024$51.00 → $14.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $BMEA
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Biomea Fusion Inc.

      SCHEDULE 13G - Biomea Fusion, Inc. (0001840439) (Subject)

      6/25/25 10:17:57 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Biomea Fusion Inc.

      8-K - Biomea Fusion, Inc. (0001840439) (Filer)

      6/20/25 5:13:37 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Biomea Fusion Inc.

      8-K - Biomea Fusion, Inc. (0001840439) (Filer)

      6/18/25 5:30:11 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Faust Elizabeth

      4 - Biomea Fusion, Inc. (0001840439) (Issuer)

      6/13/25 4:15:20 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ray Sumita

      4 - Biomea Fusion, Inc. (0001840439) (Issuer)

      6/13/25 4:15:17 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Aguiar Eric

      4 - Biomea Fusion, Inc. (0001840439) (Issuer)

      6/13/25 4:15:18 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Leadership Updates

    Live Leadership Updates

    See more
    • Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

      Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a GLP-1 based therapyBiomea's next generation oral GLP-1 receptor agonist (BMF-650) filing for IND All other clinical and preclinical activities are either being partnered or closed REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 202

      5/5/25 4:05:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

      Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage development in severe insulin deficient patientsCOVALENT-111 (T2D) 52-week data anticipated in second half 2025COVALENT-112 (T1D) open label data anticipated in second half 2025BMF-650 IND application submission planned in second half 2025 REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, reported

      3/31/25 4:10:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion Announces Leadership Transition

      Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role. REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) --  Biomea Fusion, Inc. ("Biomea," or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, announced today an executive leadership change to help ensure the company realizes its full potential developing a novel therapy for diabetes. Specifically, Mick Hitchcock, a current board member since 2021, will succeed Thomas Butler as interim Chief Executive Officer. The change is effective immediately. "As a long-time member of Biomea's Board, I've had the privilege

      3/25/25 7:00:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Financials

    Live finance-specific insights

    See more
    • Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

      Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response achieved in target, beta-cell deficient patients on one or more antidiabetic agents at baseline, showing a placebo-adjusted mean reduction of 1.47% in HbA1c at Week 26 with statistical significance, after only 12 weeks of dosing icovamenib with 100 mgIcovamenib was well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events and no serious adverse events REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company

      12/17/24 8:10:00 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

      REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Tuesday, December 17, 2024 at 8:00 am EST to present topline results from COVALENT-111, the company's Phase II trial of icovamenib in patients with type 2 diabetes. Conference Call and Webcast Details Webcast of Biomea's investor update on Tuesday, December 17, 2024, at 8:00 am EST will be available to reg

      12/16/24 6:15:01 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

      Preliminary data supports BMF-500's potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemiaBMF-500 showed a favorable safety and tolerability profile, with no dose-limiting toxicities observed across all dose levelsPharmacokinetic and pharmacodynamic data confirmed on-target FMS-like tyrosine kinase 3 (FLT3) inhibition, demonstrating dose-proportional activity and good compartmental penetrationPreliminary Phase I data for BMF-500 in R/R acute leukemia patients with FLT3 gene mutations having failed gilteritinib indicated clinical activity with evidence of responses, including a first complete response with incomplete hematologic recove

      12/9/24 4:01:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biomea Fusion Inc.

      SC 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)

      11/12/24 12:31:45 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biomea Fusion Inc.

      SC 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)

      7/10/24 6:39:58 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Biomea Fusion Inc.

      SC 13G - Biomea Fusion, Inc. (0001840439) (Subject)

      4/10/24 9:45:50 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on Biomea Fusion with a new price target

      Piper Sandler resumed coverage of Biomea Fusion with a rating of Overweight and set a new price target of $7.00

      6/3/25 7:31:50 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edward Jones initiated coverage on Biomea Fusion with a new price target

      Edward Jones initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $128.00

      10/9/24 8:20:08 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion upgraded by Rodman & Renshaw with a new price target

      Rodman & Renshaw upgraded Biomea Fusion from Neutral to Buy and set a new price target of $18.00

      9/27/24 7:30:48 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hitchcock Michael J.M. bought $100,600 worth of shares (10,000 units at $10.06), increasing direct ownership by 200% to 15,000 units (SEC Form 4)

      4 - Biomea Fusion, Inc. (0001840439) (Issuer)

      10/1/24 4:30:12 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Valle Franco was granted 4,448 shares and bought $55,361 worth of shares (12,509 units at $4.43), increasing direct ownership by 66% to 42,500 units (SEC Form 4)

      4 - Biomea Fusion, Inc. (0001840439) (Issuer)

      6/12/24 4:30:07 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

      In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, outperforming the group given semaglutide aloneIcovamenib promoted healthy myotube morphology and diminished drug-induced atrophy in ex vivo 3D-engineered human myotube culturesIn severely insulin-deficient patients from the Phase II COVALENT-111 trial, icovamenib achieved a 1.0% placebo-adjusted mean HbA1c reduction and a 55% increase in C-peptide at Week 26, three weeks after last dose SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea or Biomea Fusion) (NASDAQ:

      6/23/25 7:00:00 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

      Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND filing on track for the second half of 2025; with Phase I study initiation in obese, otherwise healthy volunteers anticipated late 2025 REDWOOD CITY, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced new preclinical findings from a 28-day weight loss study in obese non-human primates evaluating BMF-650, the Company's investigational, next-generation oral

      6/18/25 7:00:00 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion Announces Pricing of Public Offering of Securities

      REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i) 19,450,000 shares of its common stock and accompanying warrants to purchase an aggregate of 19,450,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 550,000 shares of its common stock and accompanying warrants to purchase an aggregate of 550,000 shares of common stock (or pre-funded warrants in lieu thereof), at an e

      6/17/25 11:15:12 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care